Early-stage Resectable Triple-negative Breast Cancer
Released On
September 12, 2025
Expires On
March 14, 2026
Media Type
Internet
Completion Time
15 minutes
Specialty
Hematology/Oncology
Topic(s)
Breast Cancer, Oncology
Providers/Grant Support
Provided by Medical Education Resources and QDcme.
This activity is supported in part by an independent education grant Merck Sharp & Dohme LLC.
Credit Available
- Physicians — maximum of 0.25 AMA PRA Category 1 Credit™
- Nurses — 0.25 ANCC Nursing Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity is intended for community-based medical oncologists, nurse practitioners, physician associates and other members of the healthcare team who treat and/or manage patients with breast cancer.
Program Overview
Stay current with the rapidly evolving breast cancer treatment landscape through this dynamic on demand educational series, developed for oncology professionals seeking practical, evidence based strategies they can apply immediately in patient care. Delivered in a flexible, case based format, the program presents the latest data and real-world insights on biomarker driven therapy selection, optimal sequencing of novel agents, and proactive toxicity management for antibody drug conjugates, targeted therapies, and immunotherapy. Content is continuously updated with input from our steering committee of academic and community-based experts, ensuring that each module reflects the most relevant advances and clinical considerations. This ongoing expert guidance keeps the curriculum aligned with emerging science and the realities of daily practice, supporting confident, patient centered decision making across diverse care settings.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Apply genomic, immunogenic, and proteomic profiling to guide biomarker-driven treatment decisions.
- Optimize personalized treatment strategies based on latest evidence, guideline updates, and patient-specific factors.
- Implement supportive care strategies to mitigate and manage treatment related toxicities
Faculty
Planning Committee:
Aditya Bardia, MD, MPH
Professor, Department of Medicine
Director of Translational Research Integration
UCLA Health, University of California
Jonsson Comprehensive Cancer Center
Los Angeles, CA
Erika Hamilton, MD
Director, Breast and Gynecologic Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN
Reshma Mahtani, DO
Chief of Breast Medical Oncology
Miami Cancer Institute
Baptist Health South Florida
Miami, FL
Heather McArthur, MD
Associate Professor
Clinical Director, Breast Cancer Program
UT Southwestern Medical Center
Dallas, TX
Case Presenters:
Eleonora Teplinsky, MD
Head of Breast and Gynecologic Medical Oncology
Valley-Mount Sinai Comprehensive Cancer Care
Paramus, NJ
Clinical Assistant Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY
Gregory Vidal, MD
Director of Clinical Research, LSSRC
Chair, Breast Oncology program, WCCRI
Associate Professor, UTHSC
Memphis, TN
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and QDcme. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Physician Credit
Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
Medical Education Resources designates this enduring material for a maximum of 0.25 ANCC nursing contact hour. Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 0.25 contact hour.
Disclosures of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company. The authors reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:
Gregory Vidal, MD
Consultant: Roche/Genentech, Novartis, Eli Lilly, Gilead, Puma, Pfizer, AstraZeneca, Hologic, Daiichi Sankyo, Concerto AI, Stemline, Merck, Arvinas
Research: Roche/Genentech, Puma, Celcuity, Merck, BMS, Eli Lilly, AstraZeneca, Pfizer, Gilead, GlaxoSmithKline, Novartis, Tesaro, Napo
Fee: Eli Lilly, AstraZeneca, Gilead
Aditya Bardia, MD
Consultant: Pfizer, Novartis, Merck, Genentech, Gilead, AstraZeneca, Daiichi Sankyo, Alyssum, Menarini, Eli Lilly
Erika Hamilton, MD
Consultant: Accutar Biotechnology, AstraZeneca, Daiichi Sankyo, Ellipses Pharma, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Jefferies LLC, Lilly, Medical Pharma Services, Mersana, Novartis, Olema Pharmaceuticals, Pfizer, Roche/Genentech, Stemline Therapeutics, Tempus Labs, Theratechnologies, Tubulis, Verascity Science, Zentalis Pharmaceuticals
Research: Abbvie, Acerta Pharma, Accutar Biotechnology, ADC Therapeutics, AKESOBIO Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics, Cullinan, Curis, CytomX, Daiichi Sankyo, Dana Farber Cancer Inst, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Eisai, Ellipses Pharma, Elucida Oncology, EMD Serono, Fochon Pharmaceuticals, FujiFilm, G1 Therapeutics, Gilead Sciences, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, Inspirna, InventisBio, Jacobio, K-Group Beta, Kind Pharmaceuticals, Leap Therapeutics, Lilly, Loxo Oncology, Lycera, Mabspace Biosciences, Macrogenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Myriad Genetic Laboratories, Novartis, Nucana, Olema, OncoMed, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum Therapeutics, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Plexxikon, Prelude Therapeutics, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, SeaGen, Sermonix Pharmaceuticals, Shattuck Labs, Silverback Therapeutics, StemCentRx, Stemline Therapeutics, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics, Treadwell Therapeutics, Verastem, Zenith Epigenetics, Zymeworks
Reshma Mahtani, DO
Consultant: Agendia, AstraZeneca, Arvinas, Bicycle Therapeutics, Daiichi Sankyo, Genentech, Gilead, Hologic, Lilly, Novartis, Pfizer, Puma, Stemline
Heather McArthur, MD
Consultant: Gilead, Daiichi Sankyo, Genentech, AstraZeneca, Stemline, ALX, Novartis, Pfizer, Lilly, Merck
Eleonora Teplinsky, MD
Advisory: Sermo
Consultant: AstraZeneca, Daiichi Sankyo, AbbVie, Immunogen, Pfizer, Novartis
The content managers reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:
Planners at QDcme
No relevant financial relationships to disclose.
Planners at Medical Education Resources
No relevant financial relationships to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- The Start Activity button will direct you to the MyLearning Page which will show the available cases
- Choose the first module, designated with Start Here
- After the pre-test question create an account, it requires only your email and a password, less than 1 minute. The email will be your username.
- Complete the module, you will be directed back to the MyLearning Page where you may participate in additional cases or claim credit
- To evaluate and claim credit for any completed activities click on evaluate and claim credit button.
- Complete the evaluation.
- After you evaluate the activity, the system will prompt you to choose the certificate type (physician or nurse), the first, last name and degree for your certificate, and the amount of time you are claiming.
- Your certificate will be generated with the information provided.
Certificates will be emailed to the participant.
Disclosure of Unlabeled Use
Medical Education Resources requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, QDcme, and/or Merck Sharp & Dohme LLC. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
Contact Information
If you have questions regarding the certification of this activity, please contact QDcme via email at [email protected].